Skandinaviska Enskilda Banken AB publ Acquires 172,122 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Skandinaviska Enskilda Banken AB publ grew its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 13.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,432,374 shares of the company's stock after acquiring an additional 172,122 shares during the period. Skandinaviska Enskilda Banken AB publ owned 0.13% of Teva Pharmaceutical Industries worth $31,971,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of TEVA. Atria Investments Inc lifted its position in Teva Pharmaceutical Industries by 135.4% during the third quarter. Atria Investments Inc now owns 30,856 shares of the company's stock worth $556,000 after acquiring an additional 17,746 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at approximately $60,000. Victory Capital Management Inc. raised its position in shares of Teva Pharmaceutical Industries by 1.1% in the third quarter. Victory Capital Management Inc. now owns 1,928,715 shares of the company's stock valued at $34,755,000 after buying an additional 21,764 shares in the last quarter. Oppenheimer & Co. Inc. raised its position in shares of Teva Pharmaceutical Industries by 68.9% in the third quarter. Oppenheimer & Co. Inc. now owns 32,402 shares of the company's stock valued at $584,000 after buying an additional 13,215 shares in the last quarter. Finally, D Orazio & Associates Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at approximately $199,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Activity at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of the company's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.55% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Friday, March 7th. Barclays dropped their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. Bank of America decreased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Piper Sandler lifted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. Finally, UBS Group decreased their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA traded down $0.24 during midday trading on Tuesday, reaching $16.48. 9,443,011 shares of the company were exchanged, compared to its average volume of 12,810,698. The stock's 50-day moving average price is $18.19 and its 200-day moving average price is $18.28. The stock has a market cap of $18.68 billion, a P/E ratio of -11.36, a PEG ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries Limited has a one year low of $12.51 and a one year high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.